Darovasertib Plus Crizotinib Shows Early Promise in Metastatic Uveal Melanoma

Source: OncLive, April 2023

The combination of darovasertib (IDE196) and crizotinib (Xalkori) demonstrated clinical activity and an acceptable safety profile when utilized in first- and any-line patients with metastatic uveal melanoma, according to interim results from a phase 2 trial (NCT03947385).

Preliminary data were based on investigator review from an unlocked database and had a data cutoff date of March 8, 2023. Among evaluable patients who received darovasertib at a twice-daily dose of 300 mg plus crizotinib at a twice-daily dose of 200 mg as first-line treatment (n = 20), the confirmed overall response rate (ORR) by RECIST v1.1 criteria was 45%. Specifically, 9 patients experienced a partial response (PR) to treatment.

Moreover, the disease control rate (DCR) in this group was 90%. Eighteen patients achieved disease control, including 9 confirmed PRs, 1 unconfirmed PR, and 8 cases of stable disease (SD). The median progression-free survival (PFS) was approximately 7 months.